Trove
Sign In Sign Up

Sanford C. Bernstein & Company

Organization
Mentions
11
Relationships
0
Events
0
Documents
4
Also known as:
Sanford C. Bernstein
Search

Relationship Network

Loading... nodes
Interactive Network: Click nodes or edges to highlight connections and view details with action buttons. Drag nodes to reposition. Node size indicates connection count. Line color shows relationship strength: red (8-10), orange (6-7), yellow (4-5), gray (weak). Use legend and help buttons in the graph for more guidance.
No relationships found for this entity.
No events found for this entity.

HOUSE_OVERSIGHT_024025.jpg

This document is a confidential page (Control Number 257) marked with 'HOUSE_OVERSIGHT', detailing the professional biographies of five investment professionals (Kathy LaPorte, Mark Charest, Mike Dybbs, Eric Kim, and Isaac Manke) working for a firm called 'New Leaf' (New Leaf Venture Partners). The document establishes the educational and professional backgrounds of these individuals, including previous employment at major firms like Deutsche Bank, McKinsey, and BCG. The most recent date mentioned in the text is December 2013.

Investment memorandum / corporate biography profile
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_025890.jpg

This document appears to be a printout of a news article or press release compilation regarding the FDA approval and market analysis of the Regeneron/Sanofi cholesterol drug, Praluent. It details financial projections, physician surveys, and quotes from executives at Regeneron, Sanofi, and CVS Caremark regarding pricing and accessibility. While the document bears a House Oversight stamp and mentions Donald Trump in a disconnected headline, the content focuses entirely on the pharmaceutical industry.

News article / press release compilation
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_028421.jpg

This document contains text segments describing the pharmaceutical company Celgene, its former executive Mr. Hugin, and its practice of raising drug prices. Specifically, it details price hikes for the drug Revlimid, the financial impact on the company, and the human cost as exemplified by a patient, Elaine Kodish. The text also includes commentary from a financial analyst and mentions a political campaign leveraging the issue.

Data snippet containing article text
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_026364.jpg

This article discusses the new cholesterol drug, Praluent, from Regeneron and Sanofi, focusing on its high price, which is 46% higher than analyst forecasts. It details the FDA's approval for a broader patient group than expected, the potential for wide prescription by doctors despite the label, and the expected resistance from insurance companies who will likely restrict its use. The article also includes commentary from executives at Regeneron and Sanofi, as well as analysts and cardiologists, on the drug's market potential and place alongside existing treatments like statins.

News article
2025-11-19
Analysis Source
Total Received
$0.00
0 transactions
Total Paid
$0.00
0 transactions
Net Flow
$0.00
0 total transactions
No financial transactions found for this entity. Entity linking may need to be improved.
As Sender
0
As Recipient
0
Total
0
No communications found for this entity. Entity linking may need to be improved.

Discussion 0

Sign in to join the discussion

No comments yet

Be the first to share your thoughts on this epstein entity

Back to Search